Trial Site Detail

 

Drug:
IDRX-42
Trial:
A Study of IDRX-42 (GSK6042981) Versus (vs) Sunitinib in Participants With Gastrointestinal Stromal Tumors After Imatinib Therapy (StrateGIST 3)
Conditions: Gastrointestinal Stromal Tumor
Trial Status:
Recruiting

 

University of Pittsburgh Cancer Institute

5115 Centre Ave.     Floor 2
Pittsburgh , PA 15232
USA

 

Principal Investigator:
 Melissa Burgess
Contact:
 412-692-4724 burgessma@upmc.edu Scheduling: 412-530-6608
Activation Status of this Site:
 Active
Notes about this Site:
University of Pittsburgh Cancer Institute Website:

 

 

Navigating the Map

Use the plus (+) and minus (-) controls to zoom in/out.

Click and drag the map or use the arrows to move (pan) the map.

Tip: Click the marker before zooming and the map will stay centered on the marker as you zoom.